The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
September 7th 2024
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Diabetes Drug's Cancer Risk Affirmed, FDA Says
Results of a 10-year study on bladder cancer risk with pioglitazone might be better than the five-year results led the US Food and Drug Administration to re-affirm that the danger is real--though slightly less than the preliminary data showed.
FDA Approves Combination Diabetes Drug Synjardy XR
Synjardy XR, a combination of empagliflozin and metformin hydrochloride, was approved this afternoon by the FDA for glucose management in type 2 diabetics. The drug is a collaboration between Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company.
Sitagliptin Safe Option in Diabetic Patients Admitted to Hospital?
Sitagliptin tablets proved more convenient and equally safe and effective as insulin injections in achieving glycemic control for people with diabetes admitted to hospitals for medical care or surgery, a five-center study found.